Cargando…
A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy
An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing...
Autores principales: | Barbălată, Cristina Ioana, Porfire, Alina Silvia, Sesarman, Alina, Rauca, Valentin-Florian, Banciu, Manuela, Muntean, Dana, Știufiuc, Rareș, Moldovan, Alin, Moldovan, Cristian, Tomuță, Ioan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537800/ https://www.ncbi.nlm.nih.gov/pubmed/34683821 http://dx.doi.org/10.3390/pharmaceutics13101526 |
Ejemplares similares
-
Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis
por: Negrea, Giorgiana, et al.
Publicado: (2022) -
Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5‐fluorouracil in vivo
por: Luput, Lavinia, et al.
Publicado: (2020) -
In Vivo Double Targeting of C26 Colon Carcinoma Cells and Microenvironmental Protumor Processes Using Liposomal Simvastatin
por: Luput, Lavinia, et al.
Publicado: (2018) -
The Use of the QbD Approach to Optimize the Co-Loading of Simvastatin and Doxorubicin in Liposomes for a Synergistic Anticancer Effect
por: Barbalata, Cristina-Ioana, et al.
Publicado: (2022) -
A quality by design approach for the development of lyophilized liposomes with simvastatin
por: Porfire, Alina, et al.
Publicado: (2017)